Patient Education
Share your love
Researcher Cautions on Low-Level Red Light for Myopia
A cautionary note has been sounded by a researcher from the University of Houston’s College of Optometry regarding the use of low-level red light (LLRL) therapy for controlling myopia, particularly in children. Despite recent studies touting its effectiveness in reducing…
Reginald J. Sanders, M.D. Named as New President of the ASRS
Dr. Reginald J. Sanders, a distinguished physician affiliated with the Retina Group of Washington (RGW) and PRISM Vision Group, has been named as the new president of the American Society of Retina Specialists (ASRS). Dr. Sanders holds the distinction of…
Mireca Medicines Gets $1M Boost for Retinal Disease Treatment
Mireca Medicines has been awarded a $989,000 ‘Translational Research Acceleration Program Award’ from the Foundation Fighting Blindness, enabling the company to advance preclinical development of its lead product, MM238. Recognizing Mireca’s pivotal role in targeting the cGMP pathway for treating…
LASIK vs SMILE: Which Options is Right for You?
In the realm of refractive surgery, individuals seeking visual freedom are presented with a plethora of options. Two prominent procedures, SMILE (Small Incision Lenticule Extraction) and LASIK (Laser-Assisted In Situ Keratomileusis), have emerged as front-runners, each with its unique benefits…
Formosa & Cristália Partner for APP13007 Rights in Brazil
Formosa Pharmaceuticals announced a strategic licensing agreement with Cristália Produtos Químicos Farmacêuticos to secure exclusive commercialization rights for APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in Brazil. APP13007 is designed for the treatment of inflammation and pain following ocular surgery and…
WCO and CooperVision Host Myopia Management Event in LATAM
In a strategic move to advance myopia management as the standard of care, the World Council of Optometry (WCO) has teamed up with CooperVision to host its inaugural Latin America-based virtual event, “Myopia Management: From Theory to Practice.” Scheduled for…
FDA Approves Modified Axpaxli Trial by Ocular Therapeutix
Ocular Therapeutix announced that the FDA has granted approval for a modification to the special protocol assessment (SPA) agreement for the pivotal phase 3 SOL clinical trial of Axpaxli (axitinib intravitreal implant, also known as OTX-TKI). This modification marks a…
Hearing Loss is Rare in Tepezza Treatment for TED
A recent study, led by Dr. Raymond Douglas, MD, PhD, revealed that long-term hearing loss is a rare occurrence in individuals with normal audiometry at baseline following treatment with Tepezza [teprotumumab]. Published in the current issue of the prestigious journal…
Sandoz Acquires Coherus’ Ophthalmology Assets for $170M
In a strategic move aimed at strengthening its focus on oncology and alleviating debt, Coherus BioSciences has entered into a definitive agreement to divest its Cimerli (ranibizumab-eqrn) ophthalmology franchise to Sandoz for a total consideration of $170 million in cash,…
T. Boone Pickens Foundation’s $20M Donation
Founded by the late Texan visionary energy magnate and philanthropist, the T. Boone Pickens Foundation is donating a substantial sum of $20 million to the Wilmer Eye Institute, part of Johns Hopkins Medicine. This significant donation, initially announced in 2013,…